Huaijun Wang

Publications

• Molecular Imaging of Inflammation in Inflammatory Bowel Disease with a Clinically Translatable Dual-Selectin-targeted US Contrast Agent: Comparison with FDG PET/CT in a Mouse Model. Wang H, Machtaler S, Bettinger T, Lutz AM, Luong R, Bussat P, Gambhir SS, Tranquart F, Tian L, Willmann JK. Radiology. 2013; 267 (3): 818-29
• Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Wang H, Cona MM, Chen F, Yu J, Feng Y, Li J, Keyzer FD, Marchal G, Ni Y. Anticancer Drugs. 2012; 23 (1): 12-21
• Comparison between nonspecific and necrosis-avid gadolinium contrast agents in vascular disrupting agent-induced necrosis of rodent tumors at 3.0T. Wang H, Miranda Cona M, Chen F, Li J, Yu J, Feng Y, Peeters R, De Keyzer F, Marchal G, Ni Y. Invest Radiol. 2011; 46 (9): 531-8
• Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. Wang H, Marchal G, Ni Y. World J Radiol. 2011; 3 (1): 1-16
• Development, evaluation, and application of reperfused liver infarction in rats as a practical model for studying ischemic diseases and new diagnostic and therapeutic drugs Wang H, Wu X, Chen F, Jin L, Li J, Feng Y, et al. International Journal of Modelling, Identification and Control. 2010; 9 (3): 247-261
• Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y, Nuyts J, Marchal G, Ni Y. Eur Radiol. 2010; 20 (8): 2013-26